Cancer ResearchResearch PaperPaywall

Personalized Immune Therapy Reduces Melanoma Recurrence After Surgery

Adding intismeran to pembrolizumab improved two-year freedom from melanoma recurrence by 12.2 percentage points in a phase 3 trial.

Sunday, November 15, 2026 0 views
Published in N Engl J Med
An oncology nurse administering an upper-arm injection to an adult patient in a cancer treatment clinic

Summary

A personalized immune treatment helped keep high-risk melanoma from returning after surgery in a large randomized trial. Researchers assigned 1,137 patients to receive intismeran autogene or placebo, with both groups receiving pembrolizumab. After two years, 82.2% of patients receiving the combination were alive without cancer recurrence, compared with 70.0% receiving pembrolizumab plus placebo. Freedom from distant cancer spread was also higher, at 88.5% versus 80.2%. Benefits emerged after six months rather than immediately. Severe or worse adverse events occurred in 23.6% versus 20.3% of patients. Eight patients in the combination group died from adverse events, including five before receiving intismeran; this does not establish that intismeran caused those deaths. These findings support further clinical consideration, but longer overall survival remains unproven. This summary is based on the abstract only.

0:00--:--

Detailed Summary

Melanoma can return even after surgery removes all visible cancer. Researchers are testing personalized immune treatments to help prevent that return. Intismeran autogene is designed to train immune cells to recognize distinctive features of each patient's tumor. This phase 3 trial examined whether adding it to pembrolizumab, an established immune treatment, improves outcomes after surgery.

The study randomly assigned 1,137 patients with completely removed stage IIB to IV skin melanoma to receive intismeran or placebo alongside pembrolizumab. Neither patients nor investigators knew the assignment. Intismeran or placebo was injected into muscle every three weeks for nine doses. Pembrolizumab was infused every six weeks for nine cycles. Median follow-up was 24.6 months.

At 24 months, 82.2% receiving the combination were alive without recurrence, compared with 70.0% receiving pembrolizumab plus placebo. That represents a 12.2 percentage point difference. Survival without distant spread was 88.5% versus 80.2%. Both comparisons were statistically significant. However, the reported hazard estimates showed little difference before six months, with benefits emerging afterward.

These findings support personalized tumor targeting as a promising addition to treatment after melanoma surgery. They do not establish that patients live longer overall or that this approach prevents cancer in healthy adults. Patients should discuss eligibility, access, and treatment risks with their oncology team rather than assume these results apply to every melanoma diagnosis.

Severe or worse adverse events occurred in 23.6% versus 20.3% of patients. Eight patients in the combination group died from adverse events, five before receiving intismeran, so these deaths cannot simply be attributed to that treatment. The abstract does not report comparable death details for the control group. Longer follow-up is needed to assess durability and overall survival. This summary is based on the abstract only, limiting assessment of subgroup results, detailed safety findings, and methods used to manage potential bias.

Key Findings

  • Two-year recurrence-free survival reached 82.2% with intismeran plus pembrolizumab versus 70.0% with pembrolizumab plus placebo.
  • Two-year distant-metastasis-free survival was 88.5% versus 80.2%, an 8.3 percentage point improvement.
  • Benefit emerged after six months; earlier hazard estimates showed no clear difference between groups.
  • Grade 3 or higher adverse events occurred in 23.6% versus 20.3%; treatment decisions require individualized oncology assessment.
  • The abstract does not establish longer overall survival or support use for cancer prevention in healthy adults.

Methodology

INTerpath-001 was a phase 3, double-blind trial that randomized 1,137 patients with completely resected stage IIB–IV cutaneous melanoma in a 2:1 ratio to intismeran or placebo, both with pembrolizumab. The primary endpoint was investigator-assessed recurrence-free survival; key secondary endpoints included distant-metastasis-free survival and safety. Median follow-up was 24.6 months, and piecewise hazard ratios described effects before and after six months.

Study Limitations

This summary is based on the abstract only, preventing independent assessment of detailed methods, subgroup consistency, and safety attribution. Follow-up was relatively short, and overall survival results and comparative adverse-event death details were not reported in the abstract. Merck Sharp and Dohme and Moderna funded the trial.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: